Can a new antiplatelet drug outperform clopidogrel after a heart attack?

This phase III trial tests whether vicagrel, an experimental antiplatelet drug, can prevent major heart-related events better than the standard drug clopidogrel in people with acute coronary syndrome (such as a heart attack or unstable angina) who are undergoing a stent procedure. About 1,000 participants will receive either vicagrel or clopidogrel, and researchers will track the rate of heart attacks, strokes, and cardiovascular deaths over time. The goal is to see if vicagrel offers stronger protection without increasing dangerous bleeding.